How sweet is your blood? Scanbo gives an answer without poking holes in you

DMCA / Correction Notice
- Advertisement -

If you have diabetes, or have ever suspected, you’ll probably poke-your-finger-and-drop blood-on-a-stick until your finger goes numb. Finger-prick blood glucose monitoring is the de facto standard, but AI company scanbo wants to replace Droplet with some off-the-shelf diagnostic tools and a plethora of data analysis tools.

- Advertisement -

The company has developed a prototype device that combines a three-lead ECG measurement And a photoplethysmogram (PPG). The 60-second measurement is fed to a set of algorithms that can give you some very promising measurements. For starters, the device is doing non-invasive blood glucose monitoring, but the company’s founder claims it can also do blood pressure measurement.

I spoke to Ashish Raichura, the company’s founder and CEO, as part of Nerdshala’s virtual CES coverage, where he told me a little more about the technology. He also gave me a demonstration, first testing my own blood with a traditional, off-the-shelf blood glucose monitor, and then with the company’s own prototype. Measurements were 6.2 and 6.3 mmol/L respectively, which puts both devices within a few percent accuracy of each other.


“We use three electrodes for the ECG data, and an additional measurement for the PPG. We measure for 60 seconds, and then take the raw data and analyze how machine learning combines neural networks and We use deep neural networks. We combine all that data, take three machine learning algorithms, see what the result is, and then analyze glucose,” Raichura told me, when he brought the device to me. was preparing to perform. “We want to commercialize our product, and will seek US FDA approval in Health Canada.”

Scanbo’s prototype in action. (image: scanbow)

- Advertisement -

I was surprised to learn that it is possible to make a non-invasive measurement of blood sugar – most so-called non-invasive methods use a transplant or a filament sensor wire to get the readings, but The method Scanbo uses has been studied and covered in medical journals, It doesn’t appear that the FDA has yet approved any products that take this approach, so the company is certainly facing a lengthy medical approval process to bring its products to market.

The company also claims that it is capable of taking blood pressure measurements, just as you might do at home or in a doctor’s office with a blood pressure cuff.

“When we take your EKG data, we convert it to short wave transmission length,” Raichura summarizes how the company can pull off blood pressure metrics. “Based on that, we also calculate your non-invasive cuff-free blood pressure. This is another piece of algorithm that we have a patent pending.”

With all this technology in its back pocket, the company has an interesting choice to make; Is it going to start manufacturing its own hardware devices, or is there an opportunity to license the algorithms and technology to other manufacturers who already have devices with PPG and ECG capabilities on the market.

“We have two patents pending, purely on the hardware, how we designed it, how we combined the electrodes and all the sensors in such a way that we can take all the parameters at a time,” explains Raichura That’s how the company is trying to measure everything at once. “If you look at all the equipment available traditionally, you measure one thing at a time, not everything at once. You do your blood pressure once, your EKG the other time. One after the other, all sequentially. In procedures. In our case, we’re asking you to put four fingers on the device, so that we can capture all the data, and use algorithms to report different aspects of your health.”

Scanbo sees its technology as an in-house alternative to some of the current diagnostic techniques and technology.

“As a company, we are a combination of AI and med-tech,” Raichura says, and mentions that the market is starting to take notice. “With this product, we’re just getting started. Medtronic, Samsung, LG and others are already talking to us and seeing if we can collaborate with them, and we’re exploring some strategic partnerships.” We see the needs of 400 million people with type two diabetes in the world, and the majority of the population cannot afford a glucometer – not constantly paying attention to a glucose meter. We’re very, very economical, and we can bring the cost down to as low as $20 a month. There’s no biowaste, you don’t need a disposal, you don’t need strips or anything, that’s all Purely a device with machine learning algorithms and a chargeable battery.

The company is about to leverage its prototypes and clinical results to raise a seed round and begin the process of regulatory approval and eventually make a product available to the public.

Read more about CES 2022 on TechCrunch

- Advertisement -

Stay on top - Get the daily news in your inbox

Recent Articles

Related Stories